Advertisement

You are subscribed to the Drug Topics Hospital Pharmacists' Report.

Drug Topics Hospital Pharmacists' Report

eNewsletter Subscribe

Print Subscribe

Digital Edition Subscribe

November 21, 2013

Web Version  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

TODAY'S HEADLINES

ISMP warns about diluted chemotherapy doses

Improper dosing of chemotherapy in IV bags recently caused a problem among a group of patients in Canada, so the Institute for Safe Medication Practices is cautioning healthcare practitioners about chemotherapy dosing. » More

Collaborative care may not improve outcomes

Collaborative care with pharmacists helped to boost medication adherence in patients with acute coronary syndrome after hospital discharge. However, after 12- month follow-up, the proportion of patients who achieved blood pressure and LDL-cholesterol goals were not significantly different from patients treated under usual care, according to a recent study published online for JAMA Internal Medicine. » More

ADVERTISEMENT

The Obesity Epidemic
More than 78 million U.S. adults and 12 million children and adolescents are obese, and those numbers increase every day. Articles, video, whitepapers, and resources to help you adapt your practice to confront the growing epidemic.

Rare blood cancer drug approved

FDA has approved ibrutinib (Imbruvica, Pharmacyclics and Janssen) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. It is the second drug with breakthrough therapy designation to receive FDA approval. » More

Lurasidone effective for bipolar depression

Lurasidone HCl (Latuda) reduces depressive symptoms in adult patients with bipolar depression when used as monotherapy and adjunctive therapy to lithium or valproate. This flexibility is important given the multiple unmet needs of patients with bipolar depression, according to two phase 3 studies published recently in The American Journal of Psychiatry. » More

Continuing Education

New CPE mini-series: Multiple sclerosis

This month, Drug Topics offers the first of a two-part CPE series, "MTM considerations in multiple sclerosis." Earn up to 2 credits by completing this knowledge-based activity. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

 
Advertisement

Check these out, too

Walgreens HIV pharmacies raise adherence

New outcomes data on Xeljanz labels

Senate passes stricter compounding rules

U.S. drug spending to slow through 2017

Voices

Anticoagulation Update

JP at Large

View from the Zoo

Viewpoints

Regulatory and Legal

Meetings and Events

 
Powered by Modern Medicine Advanstar Medical Communications Group